Simultaneous determination of baicalin, baicalein, wogonin, berberine, palmatine and jatrorrhizine in rat plasma by liquid chromatography-tandem mass spectrometry and application in pharmacokinetic studies after oral administration of traditional Chinese medicinal preparations containing scutellaria-coptis herb couple
In Evidence-based Complementary and Alternative Medicine : eCAM, 2009
... RIPA buffer and PI3K inhibitor, LY294002, were obtained from Millipore (Billerica, MA, USA) and Cell Signaling (Danver, MA, USA), respectively ... Non-Smad pathways in TGF-beta signalingmore suppliers
In The Journal of Cell Biology, 2008
... Ser465/467 and linker region Ser245/250/255), anti-Smad2/3, anti–phospho-Akt (Thr308 and Ser 473), anti-Akt, anti-PTEN, and anti–PI3K p110-α antibodies were obtained from Cell Signaling Technology ...
Human β-Cell Proliferation and Intracellular Signaling Part 2: Still Driving in the Dark Without a Road Map.
Ann Arbor, United States. In Diabetes, 31 Mar 2014
In a previous Perspectives in Diabetes article, we discussed what was known regarding several important intracellular signaling pathways in rodent β-cells, including the insulin receptor substrate/phosphatidylinositol-3 kinase/Akt (IRS-PI3K-Akt) pathways, glycogen synthase kinase-3 (GSK3) and mammalian target of rapamycin (mTOR) S6 kinase pathways, protein kinase Cζ (PKCζ) pathways, and their downstream cell-cycle molecular targets, and contrasted that ample knowledge to the small amount of complementary data on human β-cell intracellular signaling pathways.
PI3K and cancer: lessons, challenges and opportunities.
Irvine, United States. In Nat Rev Drug Discov, 03 Mar 2014
The central role of phosphoinositide 3-kinase (PI3K) activation in tumour cell biology has prompted a sizeable effort to target PI3K and/or downstream kinases such as AKT and mammalian target of rapamycin (mTOR) in cancer.
Jejunal Leptin-PI3K Signaling Lowers Glucose Production.
Toronto, Canada. In Cell Metab, 07 Feb 2014
We report here that intrajejunal leptin administration activates jejunal leptin receptors and signals through a phosphatidylinositol 3-kinase (PI3K)-dependent and signal transducer and activator of transcription 3 (STAT3)-independent signaling pathway to lower glucose production in healthy rodents.
Turning Off AKT: PHLPP as a Drug Target.
More papers using
San Diego, United States. In Annu Rev Pharmacol Toxicol, 06 Feb 2014
In 2005, the discovery of a family of protein phosphatases whose members directly dephosphorylate and inactivate AKT introduced a new negative regulator of the phosphoinositide 3-kinase (PI3K) oncogenic pathway.